###begin article-title 0
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
Deafblindness in French Canadians from Quebec: a predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Genetic characterisation of 15 French Canadian patients from different regions of the province of Quebec who were clinically diagnosed as USH1 reveals that carriers of the c.216G>A-allele haplotype belong to the early founders of both the Acadian and the Quebec population.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 258 264 <span type="species:ncbi:9606">people</span>
Usher syndrome type 1 (USH1) is the leading cause of deafblindness. In most populations, many private mutations are distributed across the five known USH1 genes. We investigated patients from the French Canadian population of Quebec (approximately 6 million people) that descends from about 8,500 French settlers who colonized the St Lawrence River valley between 1608 and 1759. We hypothesized that founder mutations in USH1 genes exist in this population.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
We have genetically characterized 15 patients from different regions of Quebec who were clinically diagnosed as USH1. Of these cases, 60% carried mutations of the USH1C gene, a genetic subtype that is rare outside the Acadian population. We have discovered a founder effect of the c.216G>A mutation, which has previously been designated the 'Acadian allele' because it accounts for virtually all Acadian USH1 cases. It represents 40% of disease alleles in Quebec, and a carrier of c.216G>A was identified in the general population. Mutations in other genes, except CDH23, are very rare.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 63 71 <span type="species:ncbi:9606">children</span>
Based on our findings, approximately 0.5% of congenitally deaf children in Quebec are at risk of developing retinal degeneration due to homozygosity for c.216G>A. Although the Acadians and French Canadians from Quebec are descended from French ancestors, they have always been considered genetically distinct. The genetic conditions common in Quebec are generally not found in Acadians, or they are due to different mutations. Our results, however, show that carriers of the c.216G>A allele haplotype belonged to the early founders of both the Acadian and the Quebec population.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 658 669 658 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A/USH1B</italic>
###xml 687 698 687 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23/USH1D</italic>
###xml 740 752 740 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH15/USH1F</italic>
###xml 775 780 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SANS </italic>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1G</italic>
###xml 813 819 813 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 922 928 922 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 1093 1099 1093 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1F </italic>
###xml 1107 1112 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
Usher syndrome (USH) is an autosomal recessive condition characterized by sensorineural hearing loss, variable vestibular dysfunction, and visual impairment due to retinitis pigmentosa. It is the leading cause of deafblindness, with a general prevalence of 2 to 6.2 in 100,000 [1,2]. Three clinical subtypes are distinguished, with type 1 (USH1; MIM 276900) representing the most severe subtype with profound congenital deafness, vestibular dysfunction, and prepubertal onset of retinitis pigmentosa. To date, five USH1 genes have been identified [3-10]. In a recent study on USH1 patients from the US and the UK, 39% of patients had mutations in myosin-7A (MYO7A/USH1B) or cadherin-23 (CDH23/USH1D), 11% had mutations in protocadherin-15 (PCDH15/USH1F), 7% had mutations in SANS (USH1G), and 7% had mutations in USH1C (non-Acadians) [11]. These proportions are in line with most investigations of other populations where MYO7A is the most commonly mutated gene in USH1. However, in the Ashkenazi Jewish population and the Acadian population of the Southern United States, founder effects for USH1F and for USH1C, respectively, lead to locally high incidences of these genetic subtypes [12,13].
###end p 10
###begin p 11
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 608 614 608 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 76 82 <span type="species:ncbi:9606">people</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 910 918 <span type="species:ncbi:9606">children</span>
###xml 1347 1353 <span type="species:ncbi:9606">people</span>
The current French Canadian population of Quebec of approximately 6 million people descends from about 8,500 French settlers who colonized the St Lawrence River valley between 1608 and 1759. The 2,600 settlers who arrived before 1680 contributed about two-thirds of the current gene pool [14]. We hypothesized that one or more founder mutations in USH1 genes may exist in this population. In order to investigate this, we have evaluated 15 USH1 patients (from 15 separate families) from different parts of Quebec for mutations in all known USH1 genes. Several founder mutations were identified, including an USH1C mutation that has previously been described almost exclusively in Acadians, where it is responsible for virtually all USH1 cases. In our patients from Quebec, this mutation accounts for 40% of disease alleles, a finding that will have a major impact on diagnostic and clinical management of deaf children in Quebec. Although Acadians and Quebecers are both French Canadian, Acadia was founded four years prior to Quebec and in a geographically separate area now corresponding to New Brunswick and Nova Scotia. Acadians to a great extent came from different parts of France than do Quebecois. (the meaning of the sentence has been altered by editing; what we want to say is that Acadians came from other regions of France than Quebec people ("Quebecois" is just an alternative expression for "Quebecers") Consequently, the two populations are considered genetically distinct and do not share the same propensity for genetic disorders. However, our data for the first time provide evidence for a genetic link between the population of Quebec and the Acadians, a link that has previously been regarded as unlikely.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
USH1C: novel mutations and a wide-spread founder mutation
###end title 13
###begin p 14
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 733 739 733 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1254 1260 1254 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1396 1398 1396 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
###xml 590 597 <span type="species:ncbi:9606">patient</span>
###xml 1098 1105 <span type="species:ncbi:9606">patient</span>
###xml 1333 1340 <span type="species:ncbi:9606">patient</span>
Mutation screening in exons 1, 2, 3, 5 and 6 of the USH1C gene revealed the previously reported exon 3 mutation c.216G>A in a homozygous state in four patients (one of the two corresponding families is shown in Additional data file 1b). Another four patients with the c.216G>A mutation were found to be compound heterozygotes, carrying different USH1C mutations on the second allele: c.238-239insC in exon 3 (see Additional data file 1c), and two novel mutations, c.463C>T in exon 5 (see Additional data file 1d), and c.496+1G>T in intron 5 (two patients; see Additional data file 1e). One patient was compound heterozygous for c.ins238-239insC and a novel deletion in exon 9, c.748_759+5del (see Additional data file 1f). All novel USH1C mutations are predicted to be truncating: c.463C>T creates an in-frame stop codon (p.R155X), whereas both c.496+1G>T and c.748_759+5del probably lead to aberrant splicing. In c.496+1G>T, the transversion affects the invariant consensus sequence of the exon 5 donor splice site. A G-to-A transition at the same position has been reported previously in an USH1 patient [15]. In c.748_759+5del, the twelve last nucleotides of exon 9 and five intronic nucleotides, including the donor splice site, are deleted. In sum, USH1C mutations account for 60% of disease alleles in our French Canadian USH1 patient cohort, with c.216G>A alone accounting for 40% (Figure 1a).
###end p 14
###begin p 15
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
The silent mutation c.216G>A has previously been shown to result in aberrant splicing of the USH1C gene [16]. It has been described as a founder mutation restricted to the Acadian population ('Acadian allele'), where it accounts for virtually all USH1 cases [5,8,17] and is in complete linkage disequilibrium with the 9VNTR(t,t) allele of a 45 base-pair (bp) variable number of tandem repeat (VNTR) polymorphism in intron 5 of the USH1C gene [17].
###end p 15
###begin p 16
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 707 714 <span type="species:ncbi:9606">patient</span>
In our cohort, the c.216G>A mutation accounts for 40% of disease alleles. While all other mutations identified in our study were absent in 100 French Canadian control samples from Quebec, c.216G>A was present in a heterozygous state in one out of 227 healthy control individuals, suggesting a carrier rate of about 0.44% in the Quebec population. In order to elucidate the c.216G>A haplotype, we analyzed genotypes of 16 intragenic single nucleotide polymorphisms (SNPs), the intron 5 VNTR, and locus-specific microsatellite markers of the USH1C locus. The results were consistent with a common ancestral c.216G>A-associated haplotype in our eight patients from Quebec, a previously described Acadian USH1C patient [5] and the heterozygous healthy carrier from the Quebec population (Figure 1b). Moreover, we found evidence for historical meiotic recombinations of both intragenic SNPs and a closely flanking microsatellite marker (haplotypes 1 to 4 and 6 to 8, respectively).
###end p 16
###begin p 17
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
The insertion c.238-239insC has previously been found in several USH1 cases from Europe, Asia, and North America [11,15,18]. Despite the overall low prevalence of USH1C in most populations, c.238-239insC has been found in 14% and 12.5% of USH1 patients in the UK and Germany, respectively, which may be due to founder effects [15,18]. Haplotype analysis in our patients carrying c.238-239insC was in line with haplotype data available from European patients with that mutation (see Additional data file 2).
###end p 17
###begin p 18
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
Using data from the HapMap project, the USH1C mutations identified in our study could all be assigned to USH1C haplotypes predicted to be present in the Central European population (CEU), supporting the results of our analyses (Figure 2). Both c.216G>A and the novel p.R155X mutation originated on the most common USH1C CEU haplotype. The mutations c.238-239insC, c.496+1G>T and c.748_759+5del probably occurred independently on the background of the second most common CEU haplotype. While the haplotype associated with the insertion in our patients is centromerically restricted because of different alleles for the marker D11S1349, probably indicating an older mutation, the haplotype bearing the c.496+1G>T mutation is identical over the whole range of analyzed markers (7.9 Mb) in both patients with this mutation.
###end p 18
###begin title 19
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
CDH23 mutations
###end title 19
###begin p 20
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 243 250 <span type="species:ncbi:9606">patient</span>
Two patients were homozygous for the CDH23 mutation IVS45-9G>A and showed the same haplotype as previously reported for German patients with this mutation [19], suggesting a common origin of this mutation (see Additional data file 3). Another patient was compound heterozygous for IVS45-9G>A and a novel nonsense mutation, c.2206C>T (p.R736X). Thus, CDH23 mutations are responsible for 20% of USH1 cases in our study (Figure 1a).
###end p 20
###begin title 21
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
MYO7A and USH3A mutations
###end title 21
###begin p 22
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A</italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
###xml 9 16 <span type="species:ncbi:9606">patient</span>
###xml 112 119 <span type="species:ncbi:9606">patient</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 588 595 <span type="species:ncbi:9606">patient</span>
Only one patient in our study had mutations in MYO7A, the most common USH1 gene in most other populations; this patient was compound heterozygous for the previously reported missense mutation c.1370C>T (p.A457V) [20], and a novel nonsense mutation, c.2443C>T (p.Q815X). One of the USH1 patients investigated here was homozygous for a novel missense mutation in the USH3A gene, p.A123D (c.368C>A), which is likely to be pathogenic as p.A123 is evolutionarily conserved (data not shown) and the change was not present in controls (100 French Canadians and 93 from mixed ethnic groups). One patient did not show any pathogenic change in any USH1 gene.
###end p 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 1450 1452 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
French settlement in North America started in 1608 and occurred in mainly two regions: along the St Lawrence River (the later Quebec) and in Acadia (today corresponding to New Brunswick and Nova Scotia). The Acadians, many of whom were deported to the United States in 1755, gave rise to the later populations of Maritime Canada and to the Cajuns of the southern US. Some Acadians escaped deportation and moved to what is now Quebec. By the English conquest in 1759, French immigration stopped. Linguistic and religious barriers discouraged admixture with the mostly Protestant English-speaking new settlers. Highest birth rates occurred at pioneer fronts, that is, rural regions opened to colonization, which existed until the early 20th century. Quebec has been considered a mosaic of layered founder effects, resulting from the distinct settlers' gene pools of the respective pioneer fronts. Despite modern mobility, secularization, urbanization and immigration in the second half of the 20th century, historical founder effects still have a strong impact on medical genetics and public health in Quebec. As a result, some diseases are found more frequently or exclusively in French Canadians from Quebec than in other populations, or they have special clinical or genetic features (for example, agenesis of corpus callosum and peripheral neuropathy). Frequently, a few founder mutations account for the vast number of cases of a given phenotype [14].
###end p 24
###begin p 25
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
The genetic conditions found in Quebec are generally not found in Acadians, or they are due to different mutations (for example, oculopharyngeal muscular dystrophy) [14]. In the case of USH1, our results challenge this point of view: we have shown that the USH1C mutation c.216G>A, the 'Acadian allele', is the main cause of USH1 in Quebec, accounting for 40% of USH1 disease alleles and being found all along the St Lawrence River (Figure 1a). In Acadians, c.216G>A is responsible for virtually all USH1 cases (only one out of 44 Acadian USH1 cases has been shown not to be homozygous, but compound heterozygous for c.216G>A and c.238-239insC [17]). The 9VNTR(t,t) in intron 5 and the c.216G>A mutation are in complete linkage disequilibrium and are almost exclusively found in Acadians, raising the possibility of a recent origin of c.216G>A in this population [17]. Our data now strongly suggest that carriers of c.216G>A belong to the early founders of both the Acadian and the Quebec population (Figure 1b). This would explain its wide distribution all along the St Lawrence River valley, following the direction of the historical colonization movement (Figure 1a).
###end p 25
###begin p 26
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 509 515 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 596 601 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23</italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1D </italic>
###xml 615 621 615 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 632 637 632 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1B</italic>
###xml 829 835 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 843 844 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 968 974 968 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1425 1431 1425 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 57 64 <span type="species:ncbi:9606">peoples</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
###xml 750 757 <span type="species:ncbi:9606">patient</span>
###xml 1381 1389 <span type="species:ncbi:9606">patients</span>
USH1C has so far been considered rare outside Acadia and peoples descended from that region, accounting for 7% of USH1 cases in a recent study on US and UK patients [11]. Roux et al. [21] have performed extensive mutation screening in USH1 patients from France and found USH1C mutations in only 6% of cases. Of note, c.216G>A was not detected; this resembles the rhodopsin p.P23H mutation, which has been found in 12% of Irish-American families with autosomal dominant RP, but not in Europe [22]. Strikingly, USH1C mutations account for 60% of USH1 in the patients investigated here, followed by CDH23/USH1D (20%). MYO7A mutations (USH1B), which are responsible for the main proportion of USH1 cases in other populations, only play a minor role (one patient). To date, only six USH1-causing mutations have been identified in the USH1C gene [5,8,15]. In our collective derived from a founder population, however, we met unexpected allelic heterogeneity: five different USH1C mutations, including three novel (p.R155X, c.496+1G>T, and c.748_759+5del), were found. These novel changes, although probably rare in most cases and likely to be of recent origin at a given pioneer front in some, could clinically manifest because of the high prevalence of c.216G>A. Although digenic inheritance of type 1 has been described in USH1 [23], we did not find this pattern of inheritance in our patients. Thus, there is no indication that USH1C is involved in digenic Usher syndrome, at least probably not in combination with the other USH genes found to be mutated here.
###end p 26
###begin p 27
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 904 910 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1023 1029 1023 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 750 758 <span type="species:ncbi:9606">children</span>
###xml 823 831 <span type="species:ncbi:9606">children</span>
We show that the Quebec population is the second population in the world in which USH1C is the major genetic USH1 subtype, which is rare in all other populations studied to date. USH1 is a severely disabling disorder, causing major communication handicap due to congenital deafness and progressive retinal degeneration resulting in legal blindness in most cases. There are no official numbers describing the incidence of Usher syndrome in Quebec. However, the carrier rate of approximately 0.44% solely for the USH1C mutation c.216G>A in the Quebec population suggests an incidence of Usher syndrome type 1C of 0.5 per 100,000 (assuming random mating and complete penetrance), based on c.216G>A alone. Assuming a minimum incidence of 1 per 1,000 for children with congenital profound hearing impairment [24], 0.5% of these children may develop additional retinitis pigmentosa due to homozygosity for the USH1C mutation c.216G>A. Since 60% of USH1 cases in our study are due to other mutations (20% of which also affect the USH1C gene), and because of local founder effects (also for other USH1 subtypes such as USH1D), the incidence for USH1 may (regionally) be even higher.
###end p 27
###begin p 28
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 353 358 <span type="species:ncbi:9606">child</span>
###xml 526 531 <span type="species:ncbi:9606">child</span>
While routine testing for USH1 gene mutations is hampered by the number and size of the genes involved in most populations, our data should facilitate molecular diagnosis of deafness and Usher syndrome in Quebec (>60% of cases have a mutation in USH1C and >90% of cases can be explained by ten mutations). Knowledge that a mutation in a profoundly deaf child will result in severe visual impairment in later life is important for rehabilitative strategies: parents may be more likely to choose cochlear implantation for their child rather than visual modes of communication such as sign language.
###end p 28
###begin p 29
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH15</italic>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1F </italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 341 346 <span type="species:ncbi:10090">mouse</span>
Our findings suggest that the USH1C mutation c.216G>A is one of only a handful of common single USH1 mutations, along with founder mutations in USH3A in the Finnish and the Ashkenazi Jewish population and a PCDH15/USH1F founder allele in Ashkenazi Jews [12,25,26]; moreover, it is predominant in two populations. The recent development of a mouse model carrying the c.216G>A mutation in USH1C is an important step in the development of a specific therapeutic approach for the treatment or amelioration of this devastating condition in affected individuals with the c.216G>A mutation [27].
###end p 29
###begin title 30
Conclusion
###end title 30
###begin p 31
###xml 412 420 <span type="species:ncbi:9606">children</span>
Our study sheds new light on the colonization history of two North American regions and their populations, French Canadians from Quebec and Acadians. Moreover, the finding of a wide-spread founder mutation for an otherwise rare genetic subtype of deafblindness is of great importance to the medical community as this knowledge should strongly influence diagnostic and therapeutic management of congenitally deaf children in Quebec.
###end p 31
###begin title 32
Materials and methods
###end title 32
###begin title 33
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 33
###begin p 34
###xml 119 127 <span type="species:ncbi:9606">Children</span>
###xml 272 279 <span type="species:ncbi:9606">patient</span>
###xml 553 565 <span type="species:ncbi:9606">participants</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
French Canadian subjects from Quebec with USH1 were identified through the McGill Ocular Genetics Laboratory, Montreal Children's Hospital Research Institute, McGill University Health Center, Montreal, Quebec, Canada (see Additional data file 4 for precise origin of each patient). The study was performed according to the Declaration of Helsinki and approved by the institutional review boards of both institutions involved (ethics committees of McGill University and the University Hospital of Cologne). Written informed consent was obtained from all participants. All patients met the diagnostic criteria for USH1.
###end p 34
###begin p 35
The healthy control individuals (all had negative family history for Usher syndrome) came from all regions of Quebec.
###end p 35
###begin title 36
Detection of mutations and haplotype analyses
###end title 36
###begin p 37
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 654 659 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1B</italic>
###xml 662 668 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1D</italic>
###xml 677 682 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
###xml 688 695 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH15 </italic>
###xml 696 701 696 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1F</italic>
###xml 789 795 789 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 913 918 913 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SANS </italic>
###xml 919 924 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1G</italic>
###xml 930 936 930 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
###xml 1025 1033 <span type="species:ncbi:9606">patients</span>
Genomic DNA was extracted from venous EDTA blood samples. To identify founder mutations in USH1 patients from Quebec, we followed a combination of different strategies. We performed genotyping of polymorphic microsatellite markers closely flanking the seven USH1 loci in parallel with a mutation screening strategy. In the case of homozygosity for marker alleles of a specific USH1 locus, the coding region of the corresponding gene was sequenced. Where these approaches did not lead to the identification of the genetic subtype, we sequenced the entire coding regions of all USH1 genes, in the order of mutation prevalences in other populations: MYO7A (USH1B), CDH23 (USH1D), USH1C, and PCDH15 (USH1F). Once a mutation was identified, all other patients were screened for this change. As USH1C mutations have so far only been reported in exons 1, 2, 3, 5 and 6, these exons were sequenced first. The small genes SANS (USH1G) and USH3A (which was screened because it has previously been reported to be causative in some USH1 patients) were also analyzed by direct sequencing in parallel with microsatellites.
###end p 37
###begin p 38
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1059 1065 1059 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1095 1097 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1245 1248 1245 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dra</italic>
###xml 1266 1271 1266 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
###xml 1274 1280 1274 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsp119</italic>
###xml 1295 1300 1295 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
###xml 1303 1307 1303 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Esp3</italic>
###xml 1325 1330 1325 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C</italic>
###xml 1337 1340 1337 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nhe</italic>
###xml 1355 1360 1355 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A</italic>
###xml 1382 1388 1382 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1160 1168 <span type="species:ncbi:9606">patients</span>
PCR was carried out following standard protocols and using gene-specific primers that amplify the coding exons and adjacent intronic sequences. For amplification of locus-specific polymorphic microsatellite repeat markers, we used fluorescent dye-labeled primers. For the amplification of several markers, we applied the tailed primer method as described previously [28] (primers and protocols available on request). Purified PCR fragments were sequenced using Big Dye Terminator Cycle sequencing (Applied Biosystems, Foster City, CA, USA) and analyzed on an ABI-377 DNA sequencer by capillary electrophoresis. Microsatellite markers were also analyzed on an ABI-377 DNA sequencer and genotypes were determined by GeneScan software (Applied Biosystems). Data provided by the Genome Database [29] were used as references for allele sizes. SNPs were genotyped by either restriction enzyme digest of corresponding PCR fragments or by direct sequencing. Samples were genotyped for the presence of the 9VNTR(t,t) allele of the VNTR polymorphism in intron 5 of the USH1C gene as described previously [17]. Screening for the mutations detected in this study in other patients and in normal controls was, in part, possible by restriction enzyme digest (DraIII for c.216G>A (USH1C), Bsp119I for p.R155X (USH1C), Esp3I for c.496+1G>T (USH1C), and NheI for p.Q815X (MYO7A)). Screening for the USH1C insertion c.238-239insC in exon 3 was performed by using fluorescent dye-labeled primers for amplification of exon 3 and subsequent analysis of fragment length on the ABI-377 DNA sequencer. DNA mutation numbering of identified mutations was given based on cDNA sequences of GenBank entries given below, with +1 corresponding to the A of the ATG translation initiation codon (codon 1) in the respective reference sequence.
###end p 38
###begin title 39
Accession numbers
###end title 39
###begin p 40
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
USH1C mRNA, isoform b3 (GenBank:); CDH23 mRNA (GenBank:); MYO7A mRNA (GenBank:); USH3A mRNA (GenBank:).
###end p 40
###begin title 41
Additional data files
###end title 41
###begin p 42
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 172 176 172 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 498 502 498 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 601 605 601 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 677 681 677 681 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 773 777 773 777 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 941 945 941 945 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1162 1163 1162 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1221 1227 1221 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1332 1333 1332 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1481 1485 1481 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et a</italic>
###xml 1489 1491 1489 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2123 2124 2123 2124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 2182 2188 2182 2188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 2230 2236 2230 2236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 2439 2445 2439 2445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 2553 2559 2553 2559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 2630 2632 2630 2632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2852 2853 2852 2853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 3106 3108 3106 3108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 3131 3132 3131 3132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 3198 3204 3198 3204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 3208 3213 3208 3213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23</italic>
###xml 3214 3220 3214 3220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1D </italic>
###xml 3416 3422 3416 3422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 3449 3450 3449 3450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 3795 3796 3795 3796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 3900 3906 3900 3906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 3907 3912 3907 3912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1B</italic>
###xml 3918 3924 3918 3924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 3967 3968 3967 3968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 4055 4061 4055 4061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 4067 4072 4067 4072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1D</italic>
###xml 4117 4118 4117 4118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 4222 4229 4222 4229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH15 </italic>
###xml 4230 4235 4230 4235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1F</italic>
###xml 4244 4249 4244 4249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1G</italic>
###xml 4255 4261 4255 4261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
###xml 206 213 <span type="species:ncbi:9606">patient</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 759 766 <span type="species:ncbi:9606">patient</span>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
###xml 1127 1134 <span type="species:ncbi:9606">patient</span>
###xml 1445 1453 <span type="species:ncbi:9606">patients</span>
###xml 1546 1554 <span type="species:ncbi:9606">patients</span>
###xml 1674 1682 <span type="species:ncbi:9606">patients</span>
###xml 1931 1939 <span type="species:ncbi:9606">patients</span>
###xml 2269 2277 <span type="species:ncbi:9606">patients</span>
###xml 2298 2305 <span type="species:ncbi:9606">patient</span>
###xml 2527 2535 <span type="species:ncbi:9606">patients</span>
###xml 2794 2801 <span type="species:ncbi:9606">patient</span>
###xml 2927 2935 <span type="species:ncbi:9606">patients</span>
###xml 3054 3062 <span type="species:ncbi:9606">patients</span>
###xml 3184 3192 <span type="species:ncbi:9606">patients</span>
###xml 3527 3535 <span type="species:ncbi:9606">patients</span>
###xml 3863 3870 <span type="species:ncbi:9606">patient</span>
###xml 4035 4042 <span type="species:ncbi:9606">patient</span>
###xml 4185 4192 <span type="species:ncbi:9606">patient</span>
The following additional data are available with the online version of this paper. Additional data file 1 is a figure showing the USH1C genotypes identified in this study. (a) The family of an Acadian USH1 patient that has previously been shown to be homozygous for the Acadian founder mutation, c.216G>A [5], was available for haplotype analysis. USH1C haplotypes are represented by vertical colored bars (c.216G>A-associated haplotype in red). See Figure 1b and Figure 2 for detailed haplotypes. (b) Two brothers with homozygosity for c.216G>A, which was also found in patients 367, 1116, and 1172. (c) Compound heterozygosity for c.216G>A and c.238-239insC in two brothers. (d) Compound heterozygosity for c.216G>A and the novel nonsense mutation p.R155X (patient 475). (e) Compound heterozygosity for c.216G>A and a novel splice site mutation, c.496+1G>T, which affects the invariant donor splice site of exon 5 (patients 848 and 1115). (f) Compound heterozygosity for c.238-239insC and the novel 17 bp deletion 748_759+5del, which removes 12 exonic and five intronic base-pairs, including the donor splice site of exon 9 (patient 465). Additional data file 2 is a figure that displays the haplotypes associated with USH1C mutations c.238-239insC, p.R155X, c.748_759+5del, and c.496+1G>T. SNPs in bold are referred to in Figure 2. 'âˆ…' indicates absence of the 9VNTR(t,t) allele. European: haplotype associated with c.238-239insC in European patients as published by Zwaenepoel et al. [15]. 1-2: haplotype associated with c.238-239insC in our patients (compound heterozygosity for c.748_759+5del and c.216G>A, respectively). Common haplotypes in Quebec and European USH1 patients carrying the c.238-239insC mutation suggest that the mutation probably has recently been locally 'imported' by other ethnic communities after completion of settlement. Note different alleles for D11S1349 on the chromosome carrying c.238-239insC in patients 465 and 505, respectively. 3: haplotype associated with c.496+1G>T. 4 and 5: Haplotypes associated with novel mutations c.748_759+5del and p.R155X, respectively. Additional data file 3 is a figure that displays the haplotypes associated with CDH23 mutation IVS45-9G>A. Homozygosity for the CDH23 mutation IVS45-9G>A was found in patients 303 and 1235, while patient 860 was compound heterozygous for IVS45-9G>A and the novel nonsense mutation p.R736X. SNP alleles are given according to the genomic CDH23 sequence in 5'-3' orientation. The haplotype associated with IVS45-9G>A in Quebec patients matches with the CDH23 haplotype of two German families that we have investigated previously [19]. As in the case of c.238-239insC, this could be due to settlement of ethnic groups other than French Canadians. Note recombination event for marker D10S1759 in patient 1235. N.d. = not determined. Additional data file 4 consists of a table and a map figure illustrating the precise origins of patients investigated in this study. The map illustrates the location of the places given in the table (cities associated with patients carrying c.216G>A in red). See also Figure 1a. Additional data file 5 consists of figures illustrating the haplotypes of patients with USH1C and CDH23/USH1D mutations. Fragment length analysis is shown for microsatellite markers (GeneScan, Applied Biosystems), electropherograms for SNPs, and agarose gel electrophoresis for the VNTR in intron 5 of the USH1C gene. Additional data file 6 comprises figures that show all mutations that have been identified in USH1 patients that have been investigated in this study (electropherograms), and figures for genotyping of healthy French Canadian control individuals for these mutations (by direct sequencing, restriction enzyme digest, and fragment length analysis). Additional data file 7 contains figures that illustrate results of mutation screening in patient 1881 in the following genes: MYO7A (USH1B) and USH1C (no mutations found). Additional data file 8 contains figures that illustrate results of mutation screening in patient 1881 in the CDH23 gene (USH1D) (no mutations found). Additional data file 9 contains figures that illustrate results of mutation screening in patient 1881 in the following genes: PCDH15 (USH1F), SANS (USH1G) and USH3A (no mutations found).
###end p 42
###begin title 43
Supplementary Material
###end title 43
###begin title 44
Additional data file 1
###end title 44
###begin p 45
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 42 46 42 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 368 372 368 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 471 475 471 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 547 551 547 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 643 647 643 647 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 811 815 811 815 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 76 83 <span type="species:ncbi:9606">patient</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
###xml 629 636 <span type="species:ncbi:9606">patient</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 997 1004 <span type="species:ncbi:9606">patient</span>
USH1C genotypes identified in this study. (a) The family of an Acadian USH1 patient that has previously been shown to be homozygous for the Acadian founder mutation, c.216G>A [5], was available for haplotype analysis. USH1C haplotypes are represented by vertical colored bars (c.216G>A-associated haplotype in red). See Figure 1b and Figure 2 for detailed haplotypes. (b) Two brothers with homozygosity for c.216G>A, which was also found in patients 367, 1116, and 1172. (c) Compound heterozygosity for c.216G>A and c.238-239insC in two brothers. (d) Compound heterozygosity for c.216G>A and the novel nonsense mutation p.R155X (patient 475). (e) Compound heterozygosity for c.216G>A and a novel splice site mutation, c.496+1G>T, which affects the invariant donor splice site of exon 5 (patients 848 and 1115). (f) Compound heterozygosity for c.238-239insC and the novel 17 bp deletion 748_759+5del, which removes 12 exonic and five intronic base-pairs, including the donor splice site of exon 9 (patient 465).
###end p 45
###begin p 46
Click here for file
###end p 46
###begin title 47
Additional data file 2
###end title 47
###begin p 48
###xml 39 40 39 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et a</italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
SNPs in bold are referred to in Figure 2. 'âˆ…' indicates absence of the 9VNTR(t,t) allele. European: haplotype associated with c.238-239insC in European patients as published by Zwaenepoel et al. [15]. 1-2: haplotype associated with c.238-239insC in our patients (compound heterozygosity for c.748_759+5del and c.216G>A, respectively). Common haplotypes in Quebec and European USH1 patients carrying the c.238-239insC mutation suggest that the mutation probably has recently been locally 'imported' by other ethnic communities after completion of settlement. Note different alleles for D11S1349 on the chromosome carrying c.238-239insC in patients 465 and 505, respectively. 3: haplotype associated with c.496+1G>T. 4 and 5: Haplotypes associated with novel mutations c.748_759+5del and p.R155X, respectively.
###end p 48
###begin p 49
Click here for file
###end p 49
###begin title 50
Additional data file 3
###end title 50
###begin p 51
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 89 96 <span type="species:ncbi:9606">patient</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 585 592 <span type="species:ncbi:9606">patient</span>
Homozygosity for the CDH23 mutation IVS45-9G>A was found in patients 303 and 1235, while patient 860 was compound heterozygous for IVS45-9G>A and the novel nonsense mutation p.R736X. SNP alleles are given according to the genomic CDH23 sequence in 5'-3' orientation. The haplotype associated with IVS45-9G>A in Quebec patients matches with the CDH23 haplotype of two German families that we have investigated previously [19]. As in the case of c.238-239insC, this could be due to settlement of ethnic groups other than French Canadians. Note recombination event for marker D10S1759 in patient 1235. N.d. = not determined.
###end p 51
###begin p 52
Click here for file
###end p 52
###begin title 53
Additional data file 4
###end title 53
###begin p 54
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The map illustrates the location of the places given in the table (cities associated with patients carrying c.216G>A in red). See also Figure 1a.
###end p 54
###begin p 55
Click here for file
###end p 55
###begin title 56
Additional data file 5
###end title 56
###begin p 57
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
Fragment length analysis is shown for microsatellite markers (GeneScan, Applied Biosystems), electropherograms for SNPs, and agarose gel electrophoresis for the VNTR in intron 5 of the USH1C gene.
###end p 57
###begin p 58
Click here for file
###end p 58
###begin title 59
Additional data file 6
###end title 59
###begin p 60
###xml 48 56 <span type="species:ncbi:9606">patients</span>
All mutations that have been identified in USH1 patients that have been investigated in this study (electropherograms), and figures for genotyping of healthy French Canadian control individuals for these mutations (by direct sequencing, restriction enzyme digest, and fragment length analysis).
###end p 60
###begin p 61
Click here for file
###end p 61
###begin title 62
Additional data file 7
###end title 62
###begin p 63
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYO7A </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1B</italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 33 40 <span type="species:ncbi:9606">patient</span>
Results of mutation screening in patient 1881 in the genes MYO7A (USH1B) and USH1C (no mutations found).
###end p 63
###begin p 64
Click here for file
###end p 64
###begin title 65
Additional data file 8
###end title 65
###begin p 66
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH23 </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1D</italic>
###xml 33 40 <span type="species:ncbi:9606">patient</span>
Results of mutation screening in patient 1881 in the CDH23 gene (USH1D) (no mutations found).
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Additional data file 9
###end title 68
###begin p 69
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCDH15 </italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1F</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1G</italic>
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH3A </italic>
###xml 33 40 <span type="species:ncbi:9606">patient</span>
Results of mutation screening in patient 1881 in the genes PCDH15 (USH1F), SANS (USH1G) and USH3A (no mutations found).
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
Supported by grants BO 2954/1-1 (Deutsche Forschungsgemeinschaft) and Koeln Fortune Program, grant 113/2004 (Faculty of Medicine, University of Cologne), to HJB, and Foundation Fighting Blindness Canada and Fonds de la Recherche en Sante de Quebec, to RKK. We are indebted to the families who have participated in this study. We thank Christian Kubisch and Karin Boss for discussion and comments on the manuscript and Radu Wirth for technical support.
###end p 72
###begin article-title 73
The molecular genetics of Usher syndrome.
###end article-title 73
###begin article-title 74
The usher syndromes.
###end article-title 74
###begin article-title 75
Mutations of the protocadherin gene PCDH15 cause Usher syndrome type 1F.
###end article-title 75
###begin article-title 76
Mutations in the novel protocadherin PCDH15 cause Usher syndrome type 1F.
###end article-title 76
###begin article-title 77
A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene.
###end article-title 77
###begin article-title 78
Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D.
###end article-title 78
###begin article-title 79
Usher syndrome 1D and nonsyndromic autosomal recessive deafness DFNB12 are caused by allelic mutations of the novel cadherin-like gene CDH23.
###end article-title 79
###begin article-title 80
A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C.
###end article-title 80
###begin article-title 81
Defective myosin VIIA gene responsible for Usher syndrome type 1B.
###end article-title 81
###begin article-title 82
Usher syndrome type I G (USH1G) is caused by mutations in the gene encoding SANS, a protein that associates with the USH1C protein, harmonin.
###end article-title 82
###begin article-title 83
###xml 78 85 <span type="species:ncbi:9606">patient</span>
Characterization of Usher syndrome type I gene mutations in an Usher syndrome patient population.
###end article-title 83
###begin article-title 84
A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome.
###end article-title 84
###begin article-title 85
USH1C: a rare cause of USH1 in a non-Acadian population and a founder effect of the Acadian allele.
###end article-title 85
###begin article-title 86
Population history and its impact on medical genetics in Quebec.
###end article-title 86
###begin article-title 87
Identification of three novel mutations in the USH1C gene and detection of thirty-one polymorphisms used for haplotype analysis.
###end article-title 87
###begin article-title 88
The USH1C 216G->A splice-site mutation results in a 35-base-pair deletion.
###end article-title 88
###begin article-title 89
The USH1C 216G->A mutation and the 9-repeat VNTR(t,t) allele are in complete linkage disequilibrium in the Acadian population.
###end article-title 89
###begin article-title 90
The contribution of USH1C mutations to syndromic and non-syndromic deafness in the UK.
###end article-title 90
###begin article-title 91
###xml 19 28 19 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Identification and in vitro expression of novel CDH23 mutations of patients with Usher syndrome type 1D.
###end article-title 91
###begin article-title 92
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Evaluation of the myosin VIIA gene and visual function in patients with Usher syndrome type I.
###end article-title 92
###begin article-title 93
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Survey of the frequency of USH1 gene mutations in a cohort of Usher patients shows the importance of cadherin 23 and protocadherin 15 genes and establishes a detection rate of above 90%.
###end article-title 93
###begin article-title 94
Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline-histidine substitution (codon 23) in pedigrees from Europe.
###end article-title 94
###begin article-title 95
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 115 121 <span type="species:ncbi:9606">humans</span>
Digenic inheritance of deafness caused by mutations in genes encoding cadherin 23 and protocadherin 15 in mice and humans.
###end article-title 95
###begin article-title 96
Genetic epidemiology of hearing impairment.
###end article-title 96
###begin article-title 97
Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3.
###end article-title 97
###begin article-title 98
Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III.
###end article-title 98
###begin article-title 99
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
Ush1c216A knock-in mouse survives Katrina.
###end article-title 99
###begin article-title 100
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes.
###end article-title 100
###begin article-title 101
###xml 9 14 <span type="species:ncbi:9606">Human</span>
GDB: the Human Genome Database.
###end article-title 101
###begin article-title 102
###xml 23 28 <span type="species:ncbi:9606">human</span>
A haplotype map of the human genome.
###end article-title 102
###begin title 103
Figures and Tables
###end title 103
###begin p 104
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 93 97 93 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 701 705 701 705 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 730 736 730 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1185 1191 1185 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 1678 1684 1678 1684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 556 563 <span type="species:ncbi:9606">patient</span>
###xml 692 699 <span type="species:ncbi:9606">patient</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
###xml 1745 1753 <span type="species:ncbi:9606">patients</span>
###xml 1836 1844 <span type="species:ncbi:9606">patients</span>
###xml 2180 2187 <span type="species:ncbi:9606">patient</span>
###xml 2292 2299 <span type="species:ncbi:9606">patient</span>
###xml 2366 2374 <span type="species:ncbi:9606">patients</span>
###xml 2574 2582 <span type="species:ncbi:9606">patients</span>
USH1 gene mutations in Quebec and haplotype analysis of the USH1C founder mutation c.216G>A. (a) Distribution and proportion of USH1 gene mutations in Quebec. Numbers designate patients, colors indicate different USH1 genes. Superscript symbols indicate different mutations that are listed beside the diagram. Note that c.216G>A is present all along the St Lawrence river, suggesting that it was present from the beginning of colonization by French settlers. In sum, USH1C mutations account for 60% of USH1 cases investigated in this study. In the case of patient 1881, no mutation could be identified in any of the known USH1 genes. See Additional data file 4 for the precise origin of each patient. (b) Genomic structure of the USH1C gene and haplotype bearing the c.216G>A mutation in different patients. Constitutive exons are given in black, alternatively spliced exons in grey. Mutations identified in this study are given above. Asterisks indicate novel mutations. Designations of intragenic SNPs and polymorphic microsatellite repeat markers are given below (SNPs in bold are referred to in Figure 2). The corresponding UCSC map positions are indicated below the scheme of the USH1C gene. 'VNTR' designates the 45 bp variable number of tandem repeat polymorphism in intron 5, which is in complete linkage disequilibrium with the c.216G>A mutation. Presence of the 9VNTR(t,t) allele is indicated by '9'. Alleles of microsatellite markers are represented by numbers indicating different repeat lengths. Slashes indicate that marker alleles could not be assigned definitively to a haplotype. For biallelic SNPs, the respective nucleotide is given (according to the genomic USH1C sequence in 5'-3' orientation). Haplotype IDs and respective patients are given in the left column. Haplotypes associated with c.216G>A are in red. For patients who are compound heterozygous for c.216G>A and another mutation, only the c.216G>A-associated haplotype is shown. Recombination events are indicated by grey background. Acadian: for comparison of the c.216G>A-associated haplotype ('Acadian allele') with haplotypes in our sample, we have genotyped the family of a previously described patient with homozygosity for c.216G>A (see Additional data file 1a). As there is a recombination event in this patient for marker D11S1349, both alleles are shown. 1-4: haplotypes from patients 1172, 367, 554, and 1116 who are homozygous for c.216G>A. In the case of a recombination event, only the corresponding allele is shown. 5-7: c.216G>A-associated haplotypes from compound heterozygous patients. 8: c.216G>A-associated haplotype from healthy carrier (Q14).
###end p 104
###begin p 105
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 58 62 58 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">USH1C </italic>
###xml 559 563 559 563 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
Haplotype structure of the USH1C gene locus in Europeans. (a) Structure of the USH1C gene with relative positions of mutations identified in this study and SNPs typed by the HapMap project [30]. Rate (D') of linkage disequilibrium (LD; visualized by haploview program) is represented by different colors (highest rate of LD in dark red and lower LD in light red/white). The marked block defines potential haplotypes between selected SNPs. Note that the orientation of the graphic is opposite to Figure 1b and that SNP alleles are given in reverse complement. (b) Potential haplotypes in the European population (CEU) for four selected SNPs that have been genotyped in our study. F: putative frequency of these haplotypes in CEU as determined in the HapMap project. The 'Acadian allele', c.216G>A, and p.R155X are both located on the most prevalent haplotype predicted to account for 50% of haplotypes. c.238-239insC, c.496+1G>T and c.748_759+5del are located on the second most common haplotype.
###end p 105

